Ohm,
I am here kindly requesting you add Dengue to your comprehensive Leronlimab disease list , please see paper in NIH below:
"Dengue virus requires the CC-chemokine receptor CCR5 for replication and infection development"
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4515137/
Dengue affects many people worldwide (mostly tropical countries) and that might be why it has not been investigated before (with LL). 1,346,991 cases of dengue fever have been reported only in Latin America between January 2019 and March 2020; 1,530 people have died (from Wikipedia)
More data here: Dengue worldwide overview
https://www.ecdc.europa.eu/en/dengue-monthly#...%20figures.
There are four serotypes of the illness caused by similar viruses, and each has a different interaction with antibodies, the solution needing a more general treatment (like Vyrologix).
There is no vaccine or specific treatment currently available, the research indicates that the CC-chemokine receptor CCR5 plays a key role in Dengue virus (DENV-2) infection and it has been shown that CCR5 is a host factor required for DENV-2 replication in human and mouse macrophages.
Furthermore, patients with severe dengue fever suffer increased levels of CC chemokines including associated cytokine storms. All CCR5 ligands and CCR5 itself were observed to be expressed in dengue patients and in different dengue infection models.
Some key points from WHO:
https://www.who.int/news-room/fact-sheets/det...ere-dengue
Dengue and severe dengue:
• Dengue is a mosquito-borne viral infection.
• The virus responsible for causing dengue, is called dengue virus (DENV). There are four DENV serotypes, meaning that it is possible to be infected four times.
• Severe dengue is a leading cause of serious illness and death in some Asian and Latin American countries. It requires management by medical professionals.
• While many DENV infections produce only mild illness, DENV can cause an acute flu-like illness. Occasionally this develops into a potentially lethal complication, called severe dengue.
• There is no specific treatment for dengue/severe dengue. Early detection of disease progression associated with severe dengue, and access to proper medical care lowers fatality rates of severe dengue to below 1%.
• Dengue is found in tropical and sub-tropical climates worldwide, mostly in urban and semi-urban areas.
• The global incidence of dengue has grown dramatically in recent decades. About half of the world's population is now at risk. There are an estimated 100-400 million infections each year.
• Dengue prevention and control depends on effective vector control measures. Sustained community involvement can improve vector control efforts substantially.
Needless to say, the potential market is very large.
I am here kindly requesting you add Dengue to your comprehensive Leronlimab disease list , please see paper in NIH below:
"Dengue virus requires the CC-chemokine receptor CCR5 for replication and infection development"
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4515137/
Dengue affects many people worldwide (mostly tropical countries) and that might be why it has not been investigated before (with LL). 1,346,991 cases of dengue fever have been reported only in Latin America between January 2019 and March 2020; 1,530 people have died (from Wikipedia)
More data here: Dengue worldwide overview
https://www.ecdc.europa.eu/en/dengue-monthly#...%20figures.
There are four serotypes of the illness caused by similar viruses, and each has a different interaction with antibodies, the solution needing a more general treatment (like Vyrologix).
There is no vaccine or specific treatment currently available, the research indicates that the CC-chemokine receptor CCR5 plays a key role in Dengue virus (DENV-2) infection and it has been shown that CCR5 is a host factor required for DENV-2 replication in human and mouse macrophages.
Furthermore, patients with severe dengue fever suffer increased levels of CC chemokines including associated cytokine storms. All CCR5 ligands and CCR5 itself were observed to be expressed in dengue patients and in different dengue infection models.
Some key points from WHO:
https://www.who.int/news-room/fact-sheets/det...ere-dengue
Dengue and severe dengue:
• Dengue is a mosquito-borne viral infection.
• The virus responsible for causing dengue, is called dengue virus (DENV). There are four DENV serotypes, meaning that it is possible to be infected four times.
• Severe dengue is a leading cause of serious illness and death in some Asian and Latin American countries. It requires management by medical professionals.
• While many DENV infections produce only mild illness, DENV can cause an acute flu-like illness. Occasionally this develops into a potentially lethal complication, called severe dengue.
• There is no specific treatment for dengue/severe dengue. Early detection of disease progression associated with severe dengue, and access to proper medical care lowers fatality rates of severe dengue to below 1%.
• Dengue is found in tropical and sub-tropical climates worldwide, mostly in urban and semi-urban areas.
• The global incidence of dengue has grown dramatically in recent decades. About half of the world's population is now at risk. There are an estimated 100-400 million infections each year.
• Dengue prevention and control depends on effective vector control measures. Sustained community involvement can improve vector control efforts substantially.
Needless to say, the potential market is very large.
10
